Cargando…
Gut bacterial metabolite Urolithin A inhibits myocardial fibrosis through activation of Nrf2 pathway in vitro and in vivo
BACKGROUND: Myocardial fibrosis after myocardial infarction (MI) is one of the leading causes of cardiovascular diseases. Cardiac fibroblasts (CFs) are activated and promoted by MI to undergo myofibroblast transformation (CMT). Urolithin A (UA) is an active and effective gut metabolite derived from...
Autores principales: | Chen, Pengfei, Pei, Junyu, Wang, Xiaopu, Tai, Shi, Tang, Liang, Hu, Xinqun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8822684/ https://www.ncbi.nlm.nih.gov/pubmed/35135471 http://dx.doi.org/10.1186/s10020-022-00444-1 |
Ejemplares similares
-
Hb Levels and Sex Differences in Relation to Short-Term Outcomes in Patients With Acute Myocardial Infarction
por: Pei, Junyu, et al.
Publicado: (2021) -
Association between admission systolic blood pressure and major adverse cardiovascular events in patients with acute myocardial infarction
por: Pei, Junyu, et al.
Publicado: (2020) -
Urolithin B, a Gut Microbiota Metabolite, Reduced Susceptibility to Myocardial Arrhythmic Predisposition after Hypoxia
por: Huang, Xin, et al.
Publicado: (2022) -
Ameliorative Effects of Gut Microbial Metabolite Urolithin A on Pancreatic Diseases
por: Li, Kailin, et al.
Publicado: (2022) -
The Brain-Heart Connection in Takotsubo Syndrome: The Central Nervous System, Sympathetic Nervous System, and Catecholamine Overload
por: Wang, Xiaopu, et al.
Publicado: (2020)